Argan, Inc. reported its third-quarter fiscal 2026 results on December 4, 2025, with US$251.15 million in sales, higher net income of US$30.74 million, stronger earnings per share, and a record US$3.00 billion project backlog supported by major new power projects.

The company also lifted its quarterly dividend by 33% for a third consecutive year and emphasized its dual capability in complex natural gas and renewable projects, underscoring how its expanding backlog and balance sheet strength may influence future earnings quality and income appeal.

We’ll now examine how Argan’s record US$3.00 billion backlog reshapes the company’s investment narrative and risk-reward profile.

Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

To own Argan, you have to believe that its engineering and construction expertise in large power projects will keep translating into profitable, executable work across gas and renewables. The record US$3.00 billion backlog and solid Q3 earnings support the near term revenue and earnings catalyst, while the biggest risk remains execution on a concentrated set of complex EPC projects, where delays or cost overruns could quickly pressure margins and results. So far, this quarter’s news reinforces that risk-reward balance rather than changing it.

The most relevant recent development here is Argan’s 33% dividend increase to US$0.50 per share for a third straight year, underscoring how management is pairing a growing backlog with rising cash returns to shareholders. That income stream may appeal to investors watching how the new Texas gas projects and broader backlog convert into cash flow, especially given the lumpiness that can come with large-scale power builds.

Yet despite the record backlog, investors should be aware that Argan’s dependence on a small number of large, complex projects means...

Read the full narrative on Argan (it's free!)

Argan's narrative projects $1.5 billion revenue and $142.0 million earnings by 2028. This implies 18.1% yearly revenue growth and about a $24.8 million earnings increase from $117.2 million today.

Uncover how Argan's forecasts yield a $295.75 fair value, a 6% downside to its current price.

Ten members of the Simply Wall St Community see Argan’s fair value between US$229.49 and US$547.36, reflecting wide disagreement on upside. You might set those views against the concentration risk in Argan’s few large EPC projects and consider how that could affect future earnings resilience and project throughput.

Explore 10 other fair value estimates on Argan - why the stock might be worth 27% less than the current price!

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

A great starting point for your Argan research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Our free Argan research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Argan's overall financial health at a glance.

Every day counts. These free picks are already gaining attention. See them before the crowd does:

AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include AGX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com